Warning Letter - Endotoxins, Microbiological Weaknesses and Further Contamination
Recommendation
25 November 2026
Darmstadt
This conference is part of PharmaLab Congress 2026
The FDA found significant violations of GMP requirements for sterile medicinal products during an inspection of Fresenius Kabi USA LLC from 27 January to 18 February 2026. The main issues are inadequate investigations of deviations and product defects, an insufficiently controlled aseptic manufacturing process, and significant risks from endotoxins, microbiological contamination and biological foreign particles.
In the FDA's view, several batches of medicinal products were released despite existing indications of contamination risks. The FDA therefore considers the affected products not to be GMP-compliant and, within the meaning of US pharmaceutical law, adulterated.
1. Endotoxin issues and conspicuous bioburden findings
The FDA is particularly critical of the events associated with famotidine injections:
- In 2025 and 2026, patients reported adverse events indicating pyrogenic reactions following the use of famotidine injections.
- Previously, bioburden action limits had been exceeded several times during the manufacture of these products.
- The affected bioburden samples showed strong, confluent growth of Gram-negative bacteria.
- Despite these conspicuous microbiological findings, the affected batches were initially released because the final product tests, including sterility and endotoxin tests, had initially shown acceptable results.
- However, subsequent testing of retained samples during the handling of patient complaints revealed an endotoxin finding.
- As a result, three batches of famotidine injection were recalled.
The FDA criticises in particular that Fresenius Kabi did not regard the elevated bioburden values at the time of the batch decision as a sufficient indication of an increased endotoxin risk. The FDA makes clear that unusually high bioburden values, particularly for Gram-negative microorganisms, are an immediate warning sign and require a comprehensive investigation and a consistent assessment of possible endotoxin risks.
The FDA explicitly points out that endotoxins are not reliably retained by the filter system used. A passed final product test therefore cannot compensate for inadequate control of the upstream manufacturing processes. In the FDA's view, endotoxin prevention must be ensured above all through robust process controls and effective management of the upstream process steps.
The FDA highlights the possible health consequences of pyrogen contamination. These include, among others
- fever and pronounced inflammatory reactions,
- hypotension,
- anaphylactic shock,
- severe systemic reactions, up to and including death.
The FDA considers the adjustment of procedures announced by Fresenius Kabi for enhanced endotoxin sampling and testing in the case of Gram-negative bioburden findings to be insufficient. In the FDA's view, the following are particularly lacking: a comprehensive review of the complaint system, improved detection and escalation of pyrogen risks, a systematic retrospective batch assessment, robust CAPAs and demonstrated effectiveness checks of the CAPAs.
The FDA therefore requires a comprehensive assessment of the entire system for preventing endotoxin contamination. This should cover, among other things, the following areas:
- packaging materials and closure systems,
- starting materials and other components,
- process and utility systems used,
- process and procedural controls,
- design, maintenance and repair of equipment,
- production environment,
- environmental monitoring,
- deviation and trend investigations,
- previous endotoxin and bioburden results.
2. Microbiological contamination risks in the aseptic process
The FDA considers that Fresenius Kabi has a fundamentally inadequate system for preventing microbiological contamination of sterile medicinal products. This affects both the technical design of the equipment and the conduct of personnel, the process simulations and the monitoring of aseptic manufacturing.
Faulty media fills and inadequate process simulations
Media fill failures occurred on several aseptic manufacturing lines:
- in September and October 2024 on an aseptic line with limited barrier protection,
- in April and October 2025 on another line with a Restricted Access Barrier System.
Fresenius Kabi attributed the failures essentially to inadequate aseptic technique on the part of individual employees. However, the FDA objects that the investigations did not adequately assess why these deficient practices had not been detected by the existing observation and monitoring system during commercial production.
Furthermore, the media fills did not adequately reflect the actual manufacturing conditions:
- The maximum number of critical interventions was not realistically simulated.
- Certain recurring interventions, for example refilling stoppers or loading vials, were not adequately documented in the batch records.
- The number of units in the media fills was in some cases too small.
- Worst-case conditions were not adequately taken into account.
- The media fills therefore did not reliably reflect the product's actual exposure to contamination risks.
The FDA emphasises that media fills cannot justify unsuitable equipment design or inadequate process conditions. In particular, lines with numerous manual interventions and limited barrier protection are generally associated with an increased contamination risk and require fundamental technical and organisational improvements.
Inadequate aseptic practice and cleanroom behaviour
During the inspection, the FDA observed several behaviours that can promote contamination of the critical area. These included, among others:
- abrupt opening and closing of doors during aseptic activities,
- repeated contact of the head and upper body with parts of the barrier,
- touching or manipulating critical components and connections,
- use of clamps and hand tools in the ISO 5 area,
- frequent and high-risk corrective interventions during production.
In the FDA's view, these risks were further increased by the design of the equipment. Criticised aspects include an unfavourable layout of equipment and rooms, ergonomic deficiencies, inadequate barrier protection, frequent manual interventions and insufficient separation of the ISO 5 area from its surroundings, with the resulting potentially inadequate airflow and air quality.
The FDA requires an independent and comprehensive risk assessment of all contamination hazards. This should include, among other things, personnel and material flows, airflow, disinfection, equipment design, work procedures and all human interventions in the critical area.
3. Biological foreign particles and possible microbial contamination
Since May 2022, Fresenius Kabi has documented at least nine cases of foreign particles of biological origin, in particular hairs, during visual inspection.
The FDA considers these findings particularly critical because
- hairs were found floating freely or in direct contact with the medicinal product,
- biological foreign particles can in principle carry microbial contamination,
- such particles are associated with a loss of product quality and possibly of sterility,
- in the FDA's view, products with hair contamination must in principle be regarded as adulterated.
According to the FDA, Fresenius Kabi did not initiate investigations promptly or adequately. The FDA objects in particular that the quality unit, a company-wide expert committee and a crisis committee did not hold back or reject the affected batches, but allowed their release and distribution.
The FDA additionally criticises that
- biological foreign particles were not initially classified as a critical defect,
- the impact on products already distributed was not adequately assessed,
- no adequate investigations of retained samples for hairs or other biological foreign particles were described,
- the enhanced control of incoming closure components was not adequately explained,
- supplier audits and trend analyses for stoppers and other packaging materials were not fully presented.
The resulting requirements include, for example, a retrospective investigation of all cases of biological foreign particles, an assessment of incoming packaging controls, an analysis of defect trends and acceptance limits, an assessment of all affected batches within their shelf life, combined with an investigation of retained samples from complaints. In addition, the FDA requires a statement as to whether biological particles were found in incoming packaging materials in the past three years, and an independent assessment of the batches rejected due to hair contamination.
4. Inadequate visual inspection for particles
The FDA also considers the visual inspection programme inadequate to reliably check sterile injectable medicinal products for visible particles and other defects.
Criticised in particular are
- the classification of all non-glass particles as merely "major" rather than critical defects,
- a low and highly variable detection probability of the visual inspection systems,
- inadequate detection of glass particles,
- lack of product-specific limits for different non-glass particles,
- inadequate qualification data for the inspection systems used,
- an insufficient assessment of products already on the market.
The FDA requires a comprehensive revision of the visual inspection. This should include, among other things, appropriate classification of particles of biological origin and other defects that could compromise sterility or quality. Inspection methods, equipment and personnel should be qualified so that visible particles can be detected reproducibly.
5. Deficient investigations and faulty batch decisions
Overall, the FDA criticises that Fresenius Kabi did not adequately investigate deviations, complaints, OOS and OOL results, and process and batch failures.
According to the FDA, numerous investigations lacked, among other things, scientifically and data-based root causes, an adequate extension of the investigation scope to potentially affected products, an assessment of systemic connections, an appropriate risk assessment and CAPAs, an appropriate assessment of microbiological and pyrogen risks, and effective CAPA measures.
The FDA is particularly critical of the repeated conclusion that there was no product problem when final product tests, such as sterility, endotoxin or environmental monitoring results, were unremarkable. According to the FDA, such individual results must not lead to conspicuous bioburden findings, aseptic process failures or biological foreign particles being neglected.
Further information on the required measures and the resulting recalls can be found directly in the FDA Warning Letter.
Related GMP News
18.11.2026Supplier Qualification and Oversight in an FDA Warning Letter
11.11.2026FDA Updates how it Evaluates and Inspects Human Drug Facilities
11.11.2026FDA Warning Letter to US based Manufacturer: Sterile Manufacturing Failures
28.10.2026Inadequate Supplier Oversight and missing Tests: Lessons from an FDA Warning Letter


